WO2013011153A3 - Method for the prognosis and treatment of metastasis in breast cancer - Google Patents

Method for the prognosis and treatment of metastasis in breast cancer Download PDF

Info

Publication number
WO2013011153A3
WO2013011153A3 PCT/EP2012/064436 EP2012064436W WO2013011153A3 WO 2013011153 A3 WO2013011153 A3 WO 2013011153A3 EP 2012064436 W EP2012064436 W EP 2012064436W WO 2013011153 A3 WO2013011153 A3 WO 2013011153A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastasis
prognosis
treatment
breast cancer
breast
Prior art date
Application number
PCT/EP2012/064436
Other languages
French (fr)
Other versions
WO2013011153A2 (en
Inventor
Verena STRESING
Eder BALTZISKUETA FLOREZ
Angels SIERRA JIMÉNEZ
Original Assignee
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) filed Critical Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell)
Publication of WO2013011153A2 publication Critical patent/WO2013011153A2/en
Publication of WO2013011153A3 publication Critical patent/WO2013011153A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the diagnosis and prognosis of metastasis in breast cancer based in the determination of the expression level of PRDX2gene. It also relates to a method for diagnosis and prognosis of metastasis in breast cancer based in the determination of the expression level of ERp57/GRP58gene. Lastly, the invention refers to the use of PRDX2and/or PRDX3 inhibitors and a ROS-generating agent for the treatment and/or prevention of lung metastasis in breast canceras well as to the use of ERp57/GRP58 inhibitors for the treatment and/or prevention of bone metastasis in breast cancers.
PCT/EP2012/064436 2011-07-21 2012-07-23 Method for the prognosis and treatment of metastasis in breast cancer WO2013011153A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382250 2011-07-21
EP11382250.6 2011-07-21

Publications (2)

Publication Number Publication Date
WO2013011153A2 WO2013011153A2 (en) 2013-01-24
WO2013011153A3 true WO2013011153A3 (en) 2013-04-04

Family

ID=44583751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/064436 WO2013011153A2 (en) 2011-07-21 2012-07-23 Method for the prognosis and treatment of metastasis in breast cancer

Country Status (1)

Country Link
WO (1) WO2013011153A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113365661A (en) * 2019-01-31 2021-09-07 新加坡科技研究局 CNX/ERP57 inhibitors for the treatment or prevention of cancer
US11981729B2 (en) 2019-01-31 2024-05-14 Agency For Science, Technology And Research Method
CN110734920A (en) * 2019-10-10 2020-01-31 山东大学第二医院 lung cancer detection, treatment and prognosis targets and application

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
WO2003087312A2 (en) 2002-04-08 2003-10-23 The Johns Hopkins University Inhibition of tumor growth via peroxiredoxin 3
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
WO2006074367A2 (en) 2005-01-05 2006-07-13 Sloan-Kettering Institute For Cancer Research Method of predicting and reducing risk of metastasis of breast cancer to lung
WO2007069090A2 (en) 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
ES2338843B1 (en) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas GENOMIC FOOTPRINT OF CANCER OF MAMA.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BALTZISKUETA E ET AL: "Redox regulation of Prx II and Prx III in breast cancer metastasis to lung", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 4, no. 2, 1 March 2006 (2006-03-01), pages 170 - 171, XP024989107, ISSN: 1359-6349, [retrieved on 20060301], DOI: 10.1016/S1359-6349(06)80440-4 *
DATABASE EMBL [Online] 18 August 2010 (2010-08-18), "Sequence 500276 from Patent EP2213738.", XP002683951, retrieved from EBI accession no. EMBL:HD623560 Database accession no. HD623560 *
J.-H. KIM ET AL: "Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target", CLINICAL CANCER RESEARCH, vol. 14, no. 8, 1 January 2008 (2008-01-01), pages 2326 - 2333, XP055038713, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-4457 *
KARIHTALA P ET AL: "Peroxiredoxins in breast carcinoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 9, 15 August 2003 (2003-08-15), pages 3418 - 3424, XP002266133, ISSN: 1078-0432 *
LANDEMAINE THOMAS ET AL: "A six-gene signature predicting breast cancer lung metastasis", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 15, 1 August 2008 (2008-08-01), pages 6092 - 6099, XP002495303, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-0436 *
MARTENS JOHN W M ET AL: "Identification of a gene expression signature and pathways for breast cancer metastasizing to the liver", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 48, 1 April 2007 (2007-04-01), pages 1017 - 1018, XP001526009, ISSN: 0197-016X *
MINN ANDY J ET AL: "Genes that mediate breast cancer metastasis to lung", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 436, no. 7050, 28 July 2005 (2005-07-28), pages 518 - 524, XP002454668, ISSN: 0028-0836, DOI: 10.1038/NATURE03799 *

Also Published As

Publication number Publication date
WO2013011153A2 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
HK1208501A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
IL257330B (en) Compositions, methods and kits for diagnosis of lung cancer
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
HK1187377A1 (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
MX2013002084A (en) Biomarkers and methods of treatment.
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
RS58944B1 (en) Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
MX2015007185A (en) Use of eribulin in the treatment of breast cancer.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX2013010475A (en) Yeast-brachyury immunotherapeutic compositions.
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2011020107A3 (en) Compositions and methods for detection and treatment of breast cancer
GB2535914B (en) Biomarkers useful for detection of types, grades and stages of human breast cancer
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
MX352373B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof.
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker
WO2013169771A3 (en) Methods and compositions for the prognosis and treatment of relapsed leukemia
IN2015DN01646A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12737309

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12737309

Country of ref document: EP

Kind code of ref document: A2